ALEC ALECTOR

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference (New York, New York)
    • Monday, September 11, 2023 at 4:55 p.m. ET, fireside chat
  • H.C. Wainwright 25th Annual Global Investment Conference (New York, New York)
    • Tuesday, September 12, 2023 at 2:30 p.m. ET, corporate presentation
  • Cantor Global Healthcare Conference (New York, New York)
    • Thursday, September 28, 2023 at 8:35 a.m. ET, fireside chat

Webcasts will be available on the “Events & Presentations” page within the Investors section of the Alector website at Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit .

Alector Contacts:

Alector

Katie Hogan

202-549-0557

1AB (media)

Dan Budwick

973-271-6085

Argot Partners (investors)

Laura Perry

212.600.1902



EN
31/08/2023

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector Announces Topline Results from Latozinemab Phase 3 Trial in In...

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In the 96-week, dou...

October 21, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Host Virtual Research and Development Event Highlighting PG...

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs --Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates-- SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company’s progranulin (PGRN) franchise and ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in Upcoming Healthcare Conferences

Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2025 (New York, New York) Thursday, September 4, 2025, at 3:55 p.m. ET, fireside chat Morgan Stanley 23rd Annual Global Healthcare Conference (New York, New York) Monda...

August 28, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports Second Quarter 2025 Financial Results and Provides Bus...

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer’s disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investmen...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference C...

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The c...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch